EBA
LAB icon

Eagle Bay Advisors’s Standard BioTools LAB Stock Holding History

Eagle Bay Advisors’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-281
Closed -$492 – 584
2024
Q4 		$492 Hold
281
– – ﹤0.01% 960
2024
Q3 		$542 Hold
281
– – ﹤0.01% 1311
2024
Q2 		$497 Hold
281
– – ﹤0.01% 960
2024
Q1 		$762 Buy
+281
New +$678 ﹤0.01% 936

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eagle Bay Advisors's LAB Position: Q1 2025 in Review

Eagle Bay Advisors sold out of Standard BioTools (LAB) in Q1 2025, closing a stake of 281 shares — an estimated $492 sold.

Eagle Bay Advisors first reported a position in LAB in Q1 2024 and held it in 4 quarters. The position peaked at $762 in Q1 2024. 145 funds tracked by Wall St. Rank hold LAB as of Q1 2025.

  • Eagle Bay Advisors reported no remaining Standard BioTools position as of Q1 2025 after selling out during the quarter.
  • Eagle Bay Advisors sold 281 Standard BioTools shares in Q1 2025, an estimated $492.
  • Eagle Bay Advisors first reported a position in Standard BioTools in Q1 2024 and held it in 4 quarters.
  • Eagle Bay Advisors's Standard BioTools position peaked at $762 in Q1 2024.
  • 145 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2025.

Based on Eagle Bay Advisors's 13F filing for Q1 2025, filed 5 May 2025.